nnual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) held in San Francisco from February 12–16, Smith+Nephew showcased two innovative biological implants designed to redefine healing in soft tissue and cartilage injuries. These cutting-edge technologies reflect a strategic move towards regenerative medicine, offering alternatives that go beyond traditional mechanical repairs.
One of the highlights of the event was the debut of the CARTIHEAL AGILI-C implant, an FDA-designated breakthrough device engineered to treat osteochondral lesions. This single-stage surgical solution significantly reduces pain and accelerates recovery compared to conventional procedures. Clinical data indicate that the AGILI-C device can reduce patient-reported pain by nearly 50%, providing a compelling option for those suffering from cartilage damage in the knee. Its ability to facilitate both cartilage and bone regeneration in a single operation represents a pivotal advancement in joint preservation techniques.
Complementing this innovation is the REGENETEN bioinductive implant, which has already gained traction globally with over 100,000 rotator cuff repair procedures performed since its introduction in 2014. Designed to stimulate the body’s natural healing response, REGENETEN promotes tendon growth and enhances the repair of partial-thickness rotator cuff tears. Surgeons have reported consistently high satisfaction rates, and early clinical results suggest that the implant enables quicker recovery times and improved functional outcomes.
The significance of these implants extends beyond their individual clinical benefits. According to Dr. Sabrina Strickland, an orthopaedic surgeon and early adopter of both technologies, patients are experiencing more durable healing and reduced postoperative complications. The integration of biological principles into orthopaedic devices marks a paradigm shift in sports medicine, aligning with growing trends in personalized treatment and regenerative therapies.
The commercial availability of both implants in the United States, following rigorous FDA evaluation, is expected to accelerate their adoption across various levels of sports, from professional athletes to everyday active individuals. With strong clinical backing and increasing surgeon endorsement, Smith+Nephew’s portfolio sets a new benchmark in the treatment of musculoskeletal injuries.
As healthcare increasingly prioritizes outcomes, recovery speed, and long-term joint preservation, Smith+Nephew’s regenerative implants are poised to become essential tools in modern orthopaedic practice. This launch at AAOS 2024 signals not just new products, but a transformative direction in how orthopaedic injuries are treated in the 21st century.
